Consistent with this model, treatments with TNFα inhibitors or GC by reducing pro-inflammatory cytokines in RA patients have been shown to rapidly decrease Dkk-1 (and sclerostin) serum levels (9, 11, 22, 23). The gene discussed is DKK1; the disease is rheumatoid arthritis.